Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Monomethyl fumarate (MMF) is a small molecule and the active metabolite of dimethyl fumarate (DMF), used as an oral therapy for relapsing forms of multiple sclerosis (MS). It activates the Nrf2 pathway, modulates NF-kB, interacts with glutathione, and may inhibit pyrimidine synthesis in lymphocytes. Common side effects include flushing, gastrointestinal symptoms, and lymphocyte count reduction, necessitating regular blood monitoring.
Activates the Nrf2 pathway, modulates NF-kB, interacts with glutathione, and inhibits pyrimidine synthesis in lymphocytes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Monomethyl Fumarate (MMF).